This company has shut down. Exscientia is no longer operating — its last tracked round was a Grant in 2023.
Explore the Startup GraveyardExscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Exscientia has raised $2.3M in total funding. The most recent round was Grant. The last funding was announced in December 2023.
Exscientia's investors include BlackRock, Bill & Melinda Gates Foundation, Novo Holdings, Casdin Capital, SoftBank Vision Fund.
Exscientia is headquartered in Oxford, United Kingdom.
Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Exscientia is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exscientia — Funding & Investors." VCBacked, December 5, 2023, https://www.vcbacked.co/company/exscientia. Accessed July 25, 2026.
VCBacked. (2023). Exscientia — Funding & Investors. Retrieved July 25, 2026, from https://www.vcbacked.co/company/exscientia
{{cite web |title=Exscientia — Funding & Investors |url=https://www.vcbacked.co/company/exscientia |website=VCBacked |access-date=July 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated